A股異動 | 視源股份漲5.61% 去年收入增長24% 券商唱多
格隆匯1月28日丨視源股份漲5.61%,報77.5元,總市值516億元。視源股份披露2021年度業績快報,報吿期內,公司實現營業收入212.22億元,同比增長23.9%。報吿期內,公司實現歸屬於上市公司股東的淨利潤為16.86億元,同比下降11.34%。四季度實現營收59.40億元,同比增長26.6%,歸母淨利潤4.64億元,同比下滑6.7%,扣非後歸母淨利潤4.09億元,同比跌17.5%。中信證券隨後發佈研報稱,公司2021 年業績基本符合預期,海外業務、白電業務增速亮眼,國內教育、會議業務穩定增長。給予公司2022 年40 倍PE,對應目標價155元,維持“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.